Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA
- PMID: 16572283
- DOI: 10.1007/s10067-006-0275-5
Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA
Abstract
Introduction: Autoantibodies in rheumatoid arthritis (RA) are useful both for diagnosis and prognosis. Antibodies directed against citrullinated antigens have recently been shown to predict development of RA as well as poor outcome in early arthritis. Data on their role in established RA is limited. We studied the association of various autoantibodies in RA with its severity.
Materials and methods: A total of one hundred and twenty nine-patients with established RA was enrolled and sera were collected and stored at -70 degrees C. Data regarding erosions, deformities, and extra-articular features were collected. IgM rheumatoid factor (RF) was measured using nephelometry and value above 20 U was considered positive. IgA RF was measured by enzyme-linked immunosorbent assay (ELISA) and value above the mean+/-2 SD of normal healthy control was taken as positive. Anti-keratin antibody (AKA) was detected by indirect immunofluorescence assay using rat esophagus as substrate. Anti-cyclic citrullinated peptide (CCP) antibodies were measured by commercial ELISA and a value above 5 U was considered as positive.
Results: The prevalence of various autoantibodies was: IgM RF 82.2%, anti-CCP antibodies 82.2%, AKA 51.9%, and anti IgA RF 45%. The concordance rate of anti-CCP antibodies with IgM RF was 83%, with AKA 68%, and with IgA RF 60.5%. All but one patient positive for AKA were positive for anti-CCP antibodies. The presence of IgM RF, AKA, and anti-CCP antibody was associated with joint erosions and deformities. None of the antibodies had any association with presence of extra-articular features. No association of IgA RF was seen with erosions, deformities, or extra-articular features. Among 23 seronegative RA patients, 11 were positive for anti-CCP antibodies and 6 were AKA positive. The presence of anti-CCP antibodies was associated with presence of deformities (p<0.05).
Conclusion: Anti-CCP antibodies are present in majority of patients with established RA including seronegative patients. Both anti-CCP and AKA, in addition to conventional marker like IgM RF, are associated with severe erosive disease.
Similar articles
-
Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.Ann Rheum Dis. 2003 May;62(5):427-30. doi: 10.1136/ard.62.5.427. Ann Rheum Dis. 2003. PMID: 12695154 Free PMC article.
-
[Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].Ann Biol Clin (Paris). 2008 Mar-Apr;66(2):157-64. doi: 10.1684/abc.2008.0216. Ann Biol Clin (Paris). 2008. PMID: 18390426 French.
-
[Predictive values of anti-cyclic citrullinated peptide antibody, antikeratin antibody and rheumatoid factor in diagnosing articular erosions in patients with rheumatoid arthritis].Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 May;40(3):508-12. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009. PMID: 19627016 Chinese.
-
Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.Ann Intern Med. 2007 Jun 5;146(11):797-808. doi: 10.7326/0003-4819-146-11-200706050-00008. Ann Intern Med. 2007. PMID: 17548411 Review.
-
[Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis].Rinsho Byori. 2010 May;58(5):466-79. Rinsho Byori. 2010. PMID: 20560456 Review. Japanese.
Cited by
-
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Arthritis Care Res (Hoboken). 2012. PMID: 22473917 Free PMC article. Review. No abstract available.
-
Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?Arthritis Res Ther. 2020 Jul 25;22(1):178. doi: 10.1186/s13075-020-02269-x. Arthritis Res Ther. 2020. PMID: 32711580 Free PMC article.
-
Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.PLoS One. 2020 Dec 10;15(12):e0241189. doi: 10.1371/journal.pone.0241189. eCollection 2020. PLoS One. 2020. PMID: 33301475 Free PMC article. Clinical Trial.
-
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.Rheumatol Int. 2015 Jul;35(7):1149-61. doi: 10.1007/s00296-015-3219-z. Epub 2015 Jan 25. Rheumatol Int. 2015. PMID: 25618758
-
PADI4 and tumourigenesis.Cancer Cell Int. 2010 Mar 12;10:7. doi: 10.1186/1475-2867-10-7. Cancer Cell Int. 2010. PMID: 20222985 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous